Tilray (NASDAQ: TLRY) was once one of the top pot stocks to invest in. Today, it's a bit unclear where the company stands amid its peers. The stock's down more than 40% this year -- well worse than the Horizons Marijuana Life Sciences ETF (OTC: HMLSF) that's down just 16%. And while the company's still growing, it's hard for investors to ignore Tilray's mounting losses.
Let's take a look at the company's recent results, its level growth, and whether the stock is a buy at its current price.
A big concern for many cannabis investors right now is whether companies can get through the COVID-19 pandemic. One key consideration that should always come into play when making that assessment is cash flow.
Source Fool.com